1. Market Research
  2. > EntreMed, Inc. – Product Pipeline Review – 2013

EntreMed, Inc. – Product Pipeline Review – 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 65 pages

EntreMed, Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “EntreMed, Inc. - Product Pipeline Review - 2013” provides data on the EntreMed, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, EntreMed, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from EntreMed, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- EntreMed, Inc. - Brief EntreMed, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of EntreMed, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of EntreMed, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the EntreMed, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate EntreMed, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of EntreMed, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the EntreMed, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with EntreMed, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of EntreMed, Inc. and identify potential opportunities in those areas.

Table Of Contents

EntreMed, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
EntreMed, Inc. Snapshot 5
EntreMed, Inc. Overview 5
Key Information 5
Key Facts 5
EntreMed, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
EntreMed, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
EntreMed, Inc. - Pipeline Products Glance 12
EntreMed, Inc. Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
EntreMed, Inc. - Early Stage Pipeline Products 14
Pre-Clinical Products/Combination Treatment Modalities 14
EntreMed, Inc. - Drug Profiles 15
2ME2 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
ENMD-1198 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
ENMD-2076 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
MKC-1 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
MKC-1 + [pemetrexed disodium] 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
EntreMed, Inc. - Pipeline Products By Target 24
EntreMed, Inc. - Pipeline Products by Route of Administration 25
EntreMed, Inc. - Pipeline Products By Mechanism of Action 26
EntreMed, Inc. - Recent Pipeline Updates 28
EntreMed, Inc. - Dormant Projects 31
EntreMed, Inc. - Discontinued Pipeline Products 32
Discontinued Pipeline Product Profiles 32
2-methoxyestradiol Nanocrystal Colloidal Dispersion + [sunitinib malate] 32
2-Methoxyestradiol Nanocrystal Colloidal Dispersion + [temozolomide] 32
2ME2 33
EntreMed, Inc. - Company Statement 34
EntreMed, Inc. - Locations And Subsidiaries 37
Head Office 37
Other Locations and Subsidiaries 37
EntreMed, Inc., Recent Developments 38
EntreMed, Inc.- Press Release 38
Jan 23, 2013: EntreMed Initiates Phase II Trial In Advanced/Metastatic Soft Tissue Sarcoma 38
Jan 07, 2013: EntreMed Files New Drug Clinical Trial Application For ENMD-2076 With China SFDA To Advance Global Development Strategy 38
Jan 04, 2013: EntreMed Announces Initiation Of Second Site For Phase II Trial In Triple-negative Breast Cancer 39
Nov 09, 2010: EntreMed To Present ENMD-2076 Phase I Data In Hematological Studies At ASH Annual Meeting 40
Jul 13, 2010: EntreMed's ENMD-2076 Demonstrates Significant Anti-Cancer Activity In Multiple Myeloma Preclinical Models 40
Jun 02, 2010: EntreMed's ENMD-2076 Demonstrates Preclinical Antitumor Activity In Colorectal Cancer 41
May 11, 2010: EntreMed Initiates Second Site In ENMD-2076 Phase II Ovarian Cancer Study 42
Apr 16, 2010: EntreMed Raises Additional $3 Million To Further Support Clinical Development Of ENMD-2076 In Ovarian Cancer 43
Apr 13, 2010: EntreMed Begins Phase II Study For ENMD-2076 In Ovarian Cancer 44
Feb 16, 2010: EntreMed Receives Orphan Drug Designation For ENMD-2076 In Leukemia 45
Financial Deals Landscape 46
EntreMed, Inc., Deals Summary 46
EntreMed, Inc., Pharmaceuticals and Healthcare, Deal Details 47
Partnerships 47
EntreMed Enters Into Agreement With UTEK 47
EntreMed Enters Into Agreement With University of New South Wales And Children's Cancer Institute 48
Licensing Agreements 50
Selected Value Therapeutics Exercises Its Option Licensing Agreement With EntreMed For ENMD-2076 50
Equity Offering 52
Entremed Completes Private Placement Of Units For $11 Million 52
EntreMed Completes Registered Direct Offering For $5.1 Million 54
EntreMed Completes Registered Direct Offering Of $3 Million 56
EntreMed Completes Private Placement Of Common Stock For $2.5 Million 58
EntreMed Completes Private Placement Of $2.5 Million 60
Debt Offering 62
EntreMed Completes Private Placement Of Convertible Notes Due 2012 For $10 Million 62
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 65
Disclaimer 65



List of Tables

EntreMed, Inc., Key Information 5
EntreMed, Inc., Key Facts 5
EntreMed, Inc. - Pipeline by Indication, 2013 8
EntreMed, Inc. - Pipeline by Stage of Development, 2013 9
EntreMed, Inc. - Monotherapy Products in Pipeline, 2013 10
EntreMed, Inc. - Combination Treatment Modalities in Pipeline, 2013 11
EntreMed, Inc. - Phase II, 2013 12
EntreMed, Inc. - Phase I, 2013 13
EntreMed, Inc. - Pre-Clinical, 2013 14
EntreMed, Inc. - Pipeline By Target, 2013 24
EntreMed, Inc. - Pipeline By Route of Administration, 2013 25
EntreMed, Inc. - Pipeline Products By Mechanism of Action, 2013 27
EntreMed, Inc. - Recent Pipeline Updates, 2013 28
EntreMed, Inc. - Dormant Developmental Projects,2013 31
EntreMed, Inc. - Discontinued Pipeline Products, 2013 32
EntreMed, Inc., Subsidiaries 37
EntreMed, Inc., Deals Summary 46
EntreMed Enters Into Agreement With UTEK 47
EntreMed Enters Into Agreement With University of New South Wales And Children's Cancer Institute 48
Selected Value Therapeutics Exercises Its Option Licensing Agreement With EntreMed For ENMD-2076 50
Entremed Completes Private Placement Of Units For $11 Million 52
EntreMed Completes Registered Direct Offering For $5.1 Million 54
EntreMed Completes Registered Direct Offering Of $3 Million 56
EntreMed Completes Private Placement Of Common Stock For $2.5 Million 58
EntreMed Completes Private Placement Of $2.5 Million 60
EntreMed Completes Private Placement Of Convertible Notes Due 2012 For $10 Million 62



List of Figures

EntreMed, Inc. - Pipeline by Indication, 2013 7
EntreMed, Inc. - Pipeline by Stage of Development, 2013 9
EntreMed, Inc. - Monotherapy Products in Pipeline, 2013 10
EntreMed, Inc. - Combination Treatment Modalities in Pipeline, 2013 11
EntreMed, Inc. - Pipeline By Route of Administration, 2013 25
EntreMed, Inc. - Pipeline Products By Mechanism of Action, 2013 26

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.